Amit Bar‐Or

48.4k total citations · 8 hit papers
453 papers, 25.9k citations indexed

About

Amit Bar‐Or is a scholar working on Pathology and Forensic Medicine, Immunology and Neurology. According to data from OpenAlex, Amit Bar‐Or has authored 453 papers receiving a total of 25.9k indexed citations (citations by other indexed papers that have themselves been cited), including 275 papers in Pathology and Forensic Medicine, 144 papers in Immunology and 84 papers in Neurology. Recurrent topics in Amit Bar‐Or's work include Multiple Sclerosis Research Studies (270 papers), Peripheral Neuropathies and Disorders (69 papers) and Immunotherapy and Immune Responses (68 papers). Amit Bar‐Or is often cited by papers focused on Multiple Sclerosis Research Studies (270 papers), Peripheral Neuropathies and Disorders (69 papers) and Immunotherapy and Immune Responses (68 papers). Amit Bar‐Or collaborates with scholars based in Canada, United States and Germany. Amit Bar‐Or's co-authors include Jack P. Antel, Douglas L. Arnold, Ludwig Kappos, Rui Li, Emmanuelle Waubant, Robert J. Fox, Brenda Banwell, Martin Duddy, Craig S. Moore and Craig H. Smith and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Amit Bar‐Or

436 papers receiving 25.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

2008 1.8k citations Emmanuelle Waubant, Douglas L. Arnold et al. New England Journal of Medicine profile →
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

2012 1.3k citations Ludwig Kappos, Douglas L. Arnold et al. New England Journal of Medicine profile →
Multiple sclerosis

2018 930 citations Amit Bar‐Or et al. profile →
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

2011 538 citations Ludwig Kappos, Amit Bar‐Or et al. profile →
Distinct Effector Cytokine Profiles of Memory and Naive Human B Cell Subsets and Implication in Multiple Sclerosis

2007 508 citations Amit Bar‐Or et al. The Journal of Immunology profile →
B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cells

2012 498 citations Amit Bar‐Or et al. profile →
Serologic diagnosis of NMO

2012 404 citations Patrick Waters, Amit Bar‐Or et al. Neurology profile →
Bruton tyrosine kinase inhibitors for multiple sclerosis

2023 101 citations Amit Bar‐Or, Heinz Wiendl et al. Nature Reviews Neurology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amit Bar‐Or Canada	83	14.5k	9.1k	5.8k	5.0k	4.0k	453	25.9k
Ralf Gold Germany	78	10.4k 0.7×	7.1k 0.8×	8.1k 1.4×	6.3k 1.3×	3.9k 1.0×	780	28.2k
Tomas Olsson Sweden	92	14.4k 1.0×	10.6k 1.2×	5.5k 1.0×	5.8k 1.2×	3.8k 1.0×	679	31.2k
Moses Rodriguez United States	79	13.7k 0.9×	6.5k 0.7×	6.1k 1.1×	5.4k 1.1×	3.6k 0.9×	489	27.0k
Gavin Giovannoni United Kingdom	79	14.1k 1.0×	4.2k 0.5×	7.2k 1.2×	4.3k 0.9×	2.2k 0.6×	678	26.2k
Reinhard Hohlfeld Germany	82	10.0k 0.7×	7.6k 0.8×	6.0k 1.0×	5.6k 1.1×	2.9k 0.7×	301	23.0k
Wolfgang Brück Germany	89	14.7k 1.0×	7.1k 0.8×	6.8k 1.2×	7.7k 1.5×	8.4k 2.1×	391	32.1k
Krzysztof Selmaj Poland	61	9.5k 0.7×	5.4k 0.6×	3.6k 0.6×	4.5k 0.9×	2.3k 0.6×	338	17.7k
Bernhard Hemmer Germany	73	9.5k 0.7×	6.9k 0.8×	4.4k 0.8×	3.8k 0.8×	2.5k 0.6×	354	20.1k
Eva Havrdová Czechia	57	18.7k 1.3×	4.4k 0.5×	6.2k 1.1×	3.1k 0.6×	1.7k 0.4×	385	23.5k
Paul O’Connor Canada	52	19.7k 1.4×	4.3k 0.5×	6.9k 1.2×	3.4k 0.7×	1.8k 0.4×	152	25.1k

Countries citing papers authored by Amit Bar‐Or

Since Specialization

Citations

This map shows the geographic impact of Amit Bar‐Or's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amit Bar‐Or with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amit Bar‐Or more than expected).

Fields of papers citing papers by Amit Bar‐Or

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amit Bar‐Or. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amit Bar‐Or. The network helps show where Amit Bar‐Or may publish in the future.

Co-authorship network of co-authors of Amit Bar‐Or

This figure shows the co-authorship network connecting the top 25 collaborators of Amit Bar‐Or. A scholar is included among the top collaborators of Amit Bar‐Or based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amit Bar‐Or. Amit Bar‐Or is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bréville, Gautier, Mahdia Benkhoucha, Ayman Rezk, et al.. (2025). Pro‐Inflammatory c ‐Met ⁺ CD4 T Cells in Multiple Sclerosis. Annals of Neurology. 99(1). 261–273.

Bebo, Bruce F., Mark Allegretta, Douglas Landsman, et al.. (2022). Pathways to cures for multiple sclerosis: A research roadmap. Multiple Sclerosis Journal. 28(3). 331–345. 16 indexed citations

Fadda, Giulia, Patrick Waters, Mark Woodhall, et al.. (2022). Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria. Multiple Sclerosis Journal. 28(11). 1697–1709. 15 indexed citations

Nyirenda, Moffat, Giulia Fadda, Luke M. Healy, et al.. (2021). Pro-inflammatory adiponectin in pediatric-onset multiple sclerosis. Multiple Sclerosis Journal. 27(12). 1948–1959. 12 indexed citations

Lee, Dennis S. W., Jennifer Yam, Camille Grasmuck, et al.. (2021). CCR6 Expression on B Cells Is Not Required for Clinical or Pathological Presentation of MOG Protein–Induced Experimental Autoimmune Encephalomyelitis despite an Altered Germinal Center Response. The Journal of Immunology. 207(6). 1513–1521.

Church, Molly E., Miles C. Miller, Melissa D. Sánchez, et al.. (2021). Meningeal B Cell Clusters Correlate with Submeningeal Pathology in a Natural Model of Multiple Sclerosis. The Journal of Immunology. 207(1). 44–54. 8 indexed citations

Korsukewitz, Catharina, Stephen Reddel, Amit Bar‐Or, & Heinz Wiendl. (2020). Neurological immunotherapy in the era of COVID-19 — looking for consensus in the literature. Nature Reviews Neurology. 16(9). 493–505. 43 indexed citations

Lünemann, Jan D., Tobias Ruck, Paolo A. Muraro, Amit Bar‐Or, & Heinz Wiendl. (2020). Author Correction: Immune reconstitution therapies: concepts for durable remission in multiple sclerosis. Nature Reviews Neurology. 16(2). 125–125. 4 indexed citations

Paun, Alexandra, Michelle C. Daigneault, Steven Mortin-Toth, et al.. (2019). Association of HLA-dependent islet autoimmunity with systemic antibody responses to intestinal commensal bacteria in children. Science Immunology. 4(32). 42 indexed citations

10.

Lünemann, Jan D., Tobias Ruck, Paolo A. Muraro, Amit Bar‐Or, & Heinz Wiendl. (2019). Immune reconstitution therapies: concepts for durable remission in multiple sclerosis. Nature Reviews Neurology. 16(1). 56–62. 67 indexed citations

11.

Michel, Laure, Camille Grasmuck, Marc Charabati, et al.. (2019). Activated leukocyte cell adhesion molecule regulates B lymphocyte migration across central nervous system barriers. Science Translational Medicine. 11(518). 47 indexed citations

12.

Cohen, Jeffrey A., Giancarlo Comi, Douglas L. Arnold, et al.. (2018). Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. Multiple Sclerosis Journal. 25(9). 1255–1262. 39 indexed citations

13.

Aubert-Broche, Bérengère, Katrin Weier, Giulia Longoni, et al.. (2017). Monophasic demyelination reduces brain growth in children. Neurology. 88(18). 1744–1750. 35 indexed citations

14.

Giacomini, Paul S., et al.. (2014). Calcium Supplements and Fracture Prevention. New England Journal of Medicine. 370(5). 488–488. 5 indexed citations

15.

Giacomini, Paul S., et al.. (2014). ERCP for Gallstone Pancreatitis. New England Journal of Medicine. 370(5). 488–488. 3 indexed citations

16.

Hallett, Michael, Jack P. Antel, Amit Bar‐Or, et al.. (2014). Naive CD4 T-cell activation identifies MS patients having rapid transition to progressive MS. Neurology. 82(8). 681–690. 22 indexed citations

17.

Chitnis, Tanuja, Marc Tardieu, Maria Pia Amato, et al.. (2013). International Pediatric MS Study Group Clinical Trials Summit. Neurology. 80(12). 1161–1168. 48 indexed citations

18.

Ghassemi, Rezwan, Samson Antel, Sridar Narayanan, et al.. (2008). Lesion distribution in children with clinically isolated syndromes. Annals of Neurology. 63(3). 401–405. 59 indexed citations

19.

Antony, Joseph M., Maryam Izad, Amit Bar‐Or, et al.. (2006). Quantitative Analysis of Human Endogenous Retrovirus-W env in Neuroinflammatory Diseases. AIDS Research and Human Retroviruses. 22(12). 1253–1259. 42 indexed citations

20.

Prosser, Lisa A., Karen M. Kuntz, Amit Bar‐Or, & Milton C. Weinstein. (2003). Patient and community preferences for treatments and health states in multiple sclerosis. Multiple Sclerosis Journal. 9(3). 311–319. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact